Evaluating erythropoietin-associated tumor progression using archival tissues from a phase III clinical trial

Stem Cells

Volumn 27, Issue 9, 2009, Pages 2353-2361

  Miller, Chris P ^a   Lowe, Kimberly A ^b   Valliant Saunders, Karine ^a   Kaiser, Joringel F ^a   Mattern, Dominik ^c   Urban, Nicole ^b   Henke, Michael ^c   Blau, C Anthony ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Erythropoiesis stimulating agents; Erythropoietin; Erythropoietin receptor; Growth factors; Tumor progression

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEAT SHOCK PROTEIN 70; JANUS KINASE 2; MESSENGER RNA; PLACEBO;

ARTICLE; BREAST TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN DETERMINATION; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; TUMOR GROWTH;

BREAST NEOPLASMS; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; ERYTHROPOIETIN; FEMALE; FLOW CYTOMETRY; HEAD AND NECK NEOPLASMS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; JANUS KINASE 2; PHOSPHORYLATION; RECEPTORS, ERYTHROPOIETIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAT5 TRANSCRIPTION FACTOR;

EID: 70349313947     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.156     Document Type: Article

References (35)

1. Caro JJ, Salas M, Ward A et al. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer 2001;91:2214-2221. (Pubitemid 32552805)
2. Bennett CL, Silver SM, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 2008;299:914-924.
3. Henke M, Laszig R, Rübe C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260. (Pubitemid 37324251)
4. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-5972. (Pubitemid 46300213)
5. Wright JR, Ung YC, Julian JA et al. Randomized, double-blind, placebo- controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-1032. (Pubitemid 46596751)
6. Smith RE Jr., Aapro MS, Ludwig H et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-1050.
7. Oncologic Drugs Advisory Committee meeting briefing materials at http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4345b2-01-FDA.pdf. Accessed March 13, 2008.
8. Blau CA. Erythropoietin in cancer: Presumption of innocence? Stem Cells 2007;25:2094-2097.
9. Arcasoy MO. Erythropoiesis-stimulating agent use in cancer: Preclinical and clinical perspectives. Clin Cancer Res 2008;14:4685-4690.
10. Acs G, Acs P, Beckwith SM et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561-3565. (Pubitemid 32694960)
11. Sinclair AM, Todd MD, Forsythe K et al. Expression and function of erythropoietin receptors in tumors: Implications for the use of erythropoiesis- stimulating agents in cancer patients. Cancer 2007;110:477-488.
12. Um M, Gross AW, Lodish HF. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 2007;19:634-645.
13. Henke M, Mattern D, Pepe M et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-4713.
14. Elliott S, Busse L, Bass MB et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-1895. (Pubitemid 43289368)
15. Brines M, Grasso G, Fiordaliso F et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc Natl Acad Sci U S A 2004;101:14907-14912. (Pubitemid 39410773)
16. Ihle JN, Gilliland DG. Jak2: normal function and role in hematopoietic disorders. Curr Opin Genet Dev 2007;17:8-14.
17. Huang LJ, Constantinescu SN, Lodish HF. The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor. Mol Cell 2001;8:1327-1338.
18. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-kappaB signalling cascades. Nature 2001;412:641-647. (Pubitemid 32772276)
19. Morano KA. New tricks for an old dog: The evolving world of Hsp70. Ann N Y Acad Sci 2007;1113:1-14. (Pubitemid 350015016)
20. Sherman M, Multhoff G. Heat shock proteins in cancer. Ann N Y Acad Sci 2007;1113:192-201.
21. Ribeil JA, Zermati Y, Vandekerckhove J et al. HSP70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. Nature 2007;445:102-105. (Pubitemid 46067309)
22. Becker MT, Shores CG, Yu KK et al. Molecular assay to detect metastatic head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2004;130:21-27. (Pubitemid 38095424)
23. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007;104:973-978. (Pubitemid 46154721)
24. Phillips TM, Kim K, Vlashi E et al. Effects of recombinant erythropoietin on breast cancer-initiating cells. Neoplasia 2007;9:1122-1129. (Pubitemid 350255350)
25. Palacios R, Steinmetz M. Il-3-dependent mouse clones that express B- 220 surface antigen, contain Ig genes in germ-line configuration, and generate B lymphocytes in vivo. Cell 1985;41:727-734. (Pubitemid 15225429)
26. Inoue Y, Tsushima H, Ando K et al. Chemokine expression in human erythroid leukemia cell line AS-E2: Macrophage inflammatory protein- 3alpha/CCL20 is induced by inflammatory cytokines. Exp Hematol 2006;34:19-26. (Pubitemid 43069597)
27. Vandesompele J, De Preter K, Pattyn F et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
28. Paul I, Lappin TR, Maxwell P et al. Pre-operative plasma erythropoietin concentration and survival following surgery for non-small cell lung cancer. Lung Cancer 2006;51:329-334. (Pubitemid 43265816)
29. Fu P, Jiang X, Arcasoy MO. Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 2009;379:696-701.
30. Antonov J, Goldstein DR, Oberli A et al. Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 2005;85:1040-1050. (Pubitemid 41486428)
31. Grizzi F, Colombo P, Taverna G et al. Geometry of human vascular system: is it an obstacle for quantifying antiangiogenic therapies? Appl Immunohistochem Mol Morphol 2007;15:134-139.
32. Cronin M, Pho M, Dutta D et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42. (Pubitemid 38364587)
33. Sinclair AM, Rogers N, Busse L et al. Erythropoietin receptor transcription is neither elevated nor predictive of surface expression in human tumour cells. Br J Cancer 2008;98:1059-1067.
34. Vallet JL, Freking BA, Leymaster KA et al. Allelic variation in the erythropoietin receptor gene is associated with uterine capacity and litter size in swine. Anim Genet 2005;36:97-103.
35. Wang R, Lagakos SW, Ware JH et al. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med 2007;357:2189-2194. (Pubitemid 350146117)